Park Avenue Securities LLC Sells 27,046 Shares of Haleon plc (NYSE:HLN)

Park Avenue Securities LLC lowered its holdings in shares of Haleon plc (NYSE:HLN) by 21.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 100,621 shares of the company’s stock after selling 27,046 shares during the period. Park Avenue Securities LLC’s holdings in Haleon were worth $1,065,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Personal CFO Solutions LLC raised its position in Haleon by 17.8% during the 4th quarter. Personal CFO Solutions LLC now owns 20,600 shares of the company’s stock worth $170,000 after purchasing an additional 3,115 shares during the last quarter. Clear Street Markets LLC lifted its stake in shares of Haleon by 13,646.0% in the fourth quarter. Clear Street Markets LLC now owns 13,746 shares of the company’s stock worth $113,000 after acquiring an additional 13,646 shares during the period. Syon Capital LLC boosted its holdings in Haleon by 31.4% in the fourth quarter. Syon Capital LLC now owns 67,711 shares of the company’s stock valued at $557,000 after acquiring an additional 16,175 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Haleon by 19.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock valued at $39,619,000 after purchasing an additional 772,829 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after purchasing an additional 8,423,475 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Berenberg Bank assumed coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Haleon presently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Trading Up 1.1 %

HLN opened at $10.14 on Wednesday. The company has a fifty day moving average price of $10.13 and a two-hundred day moving average price of $9.05. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80. The company has a market cap of $46.30 billion, a P/E ratio of 33.80, a price-to-earnings-growth ratio of 3.12 and a beta of 0.26. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The firm had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period last year, the company posted $0.08 earnings per share. Analysts predict that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 1.6%. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.